What Is Wegovy?

1. What Is Wegovy?

Wegovy is a prescription semaglutide brand from Novo Nordisk. The current DailyMed Wegovy label describes Wegovy as a glucagon-like peptide-1, or GLP-1, receptor agonist and lists both Wegovy injection and Wegovy tablets.

The official Wegovy site also presents Wegovy as a brand with multiple forms, including a pill and pen-based products. That matters because older shorthand often treated Wegovy as simply “the weekly semaglutide weight-loss shot.” In current U.S. sources, that description is incomplete.

Put simply, Wegovy is semaglutide under a Wegovy-specific brand label.

2. What Is Semaglutide?

Semaglutide is the active ingredient in Wegovy. It is also the active ingredient in Ozempic and Rybelsus. That shared molecule is the reason the names are easily confused, but molecule identity does not make the products interchangeable.

The Wegovy label describes semaglutide as a GLP-1 receptor agonist. GLP-1 stands for glucagon-like peptide-1, a hormone involved in glucose and appetite signaling. GLP-1 receptor agonist medicines are designed to act on related receptor pathways.

Understanding this separation helps clear up common confusion:

For broader class background, see What Is a GLP-1?. For semaglutide-specific background, see What Is Semaglutide?.

3. Why Is Wegovy Mostly a Weight-Management Story?

Wegovy became widely known because its original U.S. approval was tied to obesity and overweight with weight-related conditions. FDA’s June 2021 consumer update stated Wegovy injection was approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition, used alongside a reduced calorie diet and increased physical activity (FDA June 2021 update).

That approval is why Wegovy sits in a different public lane than Ozempic. Ozempic is strongly associated with type 2 diabetes labeling, while Wegovy is strongly associated with weight management.

The current DailyMed label is more detailed. It lists Wegovy injection for long-term weight reduction in adults and pediatric patients aged 12 years and older with obesity, and in adults with overweight plus at least one weight-related comorbid condition. It lists Wegovy tablets for long-term weight reduction in adults with obesity or adults with overweight plus at least one weight-related comorbid condition.

4. Where Does Heart-Risk Reduction Fit?

In March 2024, the FDA approved a Wegovy injection indication to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and either obesity or overweight (FDA cardiovascular-risk announcement).

This label expansion moved Wegovy beyond a weight-management-only profile. The FDA described it as the first weight-loss medication also approved to help prevent life-threatening cardiovascular events in adults with cardiovascular disease and either obesity or overweight.

The FDA announcement noted the cardiovascular outcomes trial randomly assigned more than 17,600 participants to Wegovy or placebo. Major adverse cardiovascular events occurred in 6.5% of participants who received Wegovy compared with 8% of participants who received placebo. The current DailyMed label includes cardiovascular-risk-reduction indications for both Wegovy injection and Wegovy tablets in adults with established cardiovascular disease and either obesity or overweight.

5. What Changed With Wegovy Tablets?

The most notable recent change is that Wegovy is no longer just an injection. The official Wegovy site highlights a once-daily pill, describing it as the only FDA-approved semaglutide tablet for weight loss in adults. DailyMed lists Wegovy tablets alongside Wegovy injection under the Wegovy label.

Novo Nordisk announced in December 2025 that the FDA had approved the once-daily Wegovy pill as an oral GLP-1 medicine for obesity in the United States, with weight-management and cardiovascular-risk-reduction contexts in adults (Novo Nordisk announcement via PR Newswire).

“Wegovy” can now refer to either an injection or a tablet.

6. What Other Label Contexts Are Easy to Miss?

Wegovy’s label has grown to include metabolic dysfunction-associated steatohepatitis (MASH). In August 2025, the FDA announced that Wegovy injection was approved under accelerated approval to treat MASH in adults with moderate-to-advanced fibrosis (FDA MASH announcement).

MASH is a specific liver-disease context. The FDA noted that continued approval for this indication may depend on clinical benefit verification in a confirmatory trial. DailyMed’s indications section currently frames the MASH context specifically for Wegovy injection.

This highlights why checking current labels matters. While public shorthand often reduces Wegovy to just “weight loss,” the actual label includes significant nuance depending on the specific product format and indication.

7. Wegovy, Ozempic, and Rybelsus Are Related but Different

Wegovy, Ozempic, and Rybelsus are all semaglutide brands, but they serve different roles in labeling. Here is a high-level overview:

For more on Ozempic specifically, see What Is Ozempic?. For recordkeeping context, see Wegovy Tracker App or Semaglutide Tracker App.

8. How to Read Wegovy Information

When reading about Wegovy, separating these details can help clarify the facts:

9. What Is Wegovy FAQ

• What is Wegovy in simple terms?

  Wegovy is a Novo Nordisk brand name for prescription semaglutide products. Current U.S. labeling includes Wegovy injection and Wegovy tablets, with weight-management and cardiovascular-risk-reduction contexts that differ from Ozempic and Rybelsus.

• Is Wegovy the same thing as semaglutide?

  No. Semaglutide is the active ingredient. Wegovy is a brand name attached to specific U.S. labels. Ozempic and Rybelsus also involve semaglutide, but the brand, route, and indicated-use context are different facts.

• Is Wegovy a shot or a pill?

  Current official sources describe both Wegovy injection and Wegovy tablets. That does not mean every Wegovy product has the same route, patient population, label details, or instructions.

• How is Wegovy different from Ozempic and Rybelsus?

  At a high level, Wegovy is semaglutide branding centered on weight management and related labeled contexts. Ozempic is semaglutide branding centered on type 2 diabetes, and Rybelsus is oral semaglutide branding for type 2 diabetes.

10. Sources